Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC

Piotr Wysocki recently posted on LinkedIn:

“Martin Schuler et al. published results of their phase 2 study in Nature Medicine. The study enrolled 60 patients with histologically or cytologically confirmed NSCLC eligible for anatomic resection. Clinical stages IB, II and selected stage IIIA (T3 N1, T4 with satellite nodule in the same lung N0/N1, selected T1a–T2b N2 cases considered suitable for primary surgical approach by the multidisciplinary tumor board were eligible.

Patients were randomized between two preoperative treatments given every 14 days with nivolumab (240 mg, arm A) and nivolumab plus relatlimab (240 and 80 mg, arm B).

The results were as follows:

• Primary Endpoint: The feasibility of surgery within 43 days was achieved by all patients in the study, indicating that the preoperative treatments did not delay surgical interventions.
• Curative Resection: Achieved in 95% of patients, showing a high rate of successful surgeries.
• Pathological Response: Major pathological responses (≤10% viable tumor cells) were observed in 27% of patients receiving nivolumab alone and 30% of patients receiving the combination of nivolumab and relatlimab.
• Radiographic Response: Objective radiographic responses were seen in 10% of patients with nivolumab alone and 27% with the combination therapy.
• Survival Rates: At 12 months, disease-free survival rates were 89% (nivolumab) and 93% (combination), with overall survival rates of 93% (nivolumab) and 100% (combination).

Toxicity:

• Adverse Events: Grade ≥3 treatment-emergent adverse events were reported in 10% of patients receiving nivolumab alone and 13% of patients receiving the combination therapy, indicating a manageable safety profile.

In conclusion – the combination of anti-PD1 and anti-LAG3 antibodies demonstrates high activity and a good safety profile as a neoadjuvant treatment in NSCLC patients.”

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Authors: Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm and Clemens Aigner.

Source: Piotr Wysocki/LinkedIn